Here's Why Amgen (AMGN) is a Strong Growth Stock

Company Overview - Amgen is one of the largest biotech companies globally, with a strong presence in oncology, cardiovascular disease, inflammation, bone health, and rare diseases markets [12] - The company has developed successful drugs such as Epogen and Neupogen, and launched next-generation products like Aranesp and Neulasta [12] - Amgen's acquisition of Immunex Corporation provided access to the blockbuster drug Enbrel, although older drugs are facing declining sales due to competition [12] Financial Performance - Amgen has a Zacks Rank of 3 (Hold) and a VGM Score of A, indicating a solid position in the market [13] - The company is forecasted to achieve year-over-year earnings growth of 4.6% for the current fiscal year [13] - Recent upward revisions in earnings estimates by 10 analysts have increased the Zacks Consensus Estimate by $0.13 to $20.76 per share [13] - Amgen has an average earnings surprise of 8.3%, suggesting a positive trend in financial performance [13] Investment Potential - With a solid Zacks Rank and top-tier Growth and VGM Style Scores, Amgen is recommended for investors' consideration [14]